Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimising testing for phospholipid antibodies.

M Helbert1, S Bodger, J Cavenagh

  • 1Department of Immunopathology, St Bartholomews and the London NHS Trust, London EC1A 7BE, UK. mrhelbert@mds.qmw.ac.uk

Journal of Clinical Pathology
|September 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

British journal of cancer·2017
Same author

Cerebral tuberculosis in a patient with systemic lupus erythematosus following cyclophosphamide treatment: a case report.

Lupus·2017
Same author

Burden of illness in systemic lupus erythematosus: results from a UK patient and carer online survey.

Lupus·2017
Same author

Acute Myeloid Leukaemia Following Matched Allogeneic Bone Marrow Transplantation for T-Cell Lymphoblastic Lymphoma.

Leukemia & lymphoma·2016
Same author

Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies.

British journal of cancer·2015
Same author

Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD.

Bone marrow transplantation·2014
Same journal

Defining biochemical, pathological and molecular factors prognostic in terms of disease control and survival in high-grade extremity soft tissue sarcoma: a scoping review.

Journal of clinical pathology·2026
Same journal

MILGDF: a multi-task, instance-level supervised model for oral squamous cell carcinoma integrating local-global attention and dynamic decision fusion.

Journal of clinical pathology·2026
Same journal

Paediatric B-lymphoblastic leukaemia with low peripheral blasts: a potential diagnostic pitfall.

Journal of clinical pathology·2026
Same journal

MRI-targeted versus systematic needle core biopsies in prostate cancer: a patient-based analysis of potential diagnostic and biologic underestimation.

Journal of clinical pathology·2026
Same journal

Basal plasmacytosis and eosinophilia for distinguishing inflammatory bowel disease from gastrointestinal tuberculosis on mucosal biopsy.

Journal of clinical pathology·2026
Same journal

Assay-dependent variability in free thyroxine (FT4): differential interference related to immunoassay design in a patient with subclinical hypothyroidism.

Journal of clinical pathology·2026
See all related articles

Anticardiolipin (ACL) and anti-beta2 glycoprotein 1 (beta2gp1) assays show comparable performance in diagnosing antiphospholipid syndrome (APS). Meta-analysis reveals beta2gp1 has higher specificity, while ACL has lower sensitivity for APS diagnosis.

Area of Science:

  • Immunology
  • Clinical Diagnostics
  • Rheumatology

Background:

  • Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications.
  • Accurate diagnostic assays are crucial for timely management of APS.
  • Enzyme-linked immunosorbent assays (ELISAs) for anticardiolipin (ACL) and anti-beta2 glycoprotein 1 (beta2gp1) are commonly used in APS diagnosis.

Purpose of the Study:

  • To compare the diagnostic performance of ACL and anti-beta2gp1 ELISAs for antiphospholipid syndrome (APS).
  • To integrate the findings into a meta-analysis of existing published data on these assays.

Main Methods:

  • Optimization and assessment of three commercial ACL ELISAs and one in-house beta2gp1 assay using 124 sera samples.
  • Inclusion of assay performance data from a Medline search for meta-analysis.

Related Experiment Videos

Main Results:

  • A non-quantitative ACL assay demonstrated comparable diagnostic performance to the anti-beta2gp1 assay for APS.
  • Meta-analysis indicated that the anti-beta2gp1 assay possesses higher specificity but lower sensitivity compared to the ACL assay.
  • Neither assay was found to be perfect in APS diagnosis.

Conclusions:

  • The ACL assay is valuable for investigating thrombosis in the absence of clear underlying pathology.
  • The enhanced specificity of the anti-beta2gp1 assay is beneficial in cases involving infection, connective tissue disease, or atheroma.
  • Assay selection for APS diagnosis should consider the clinical context and specific diagnostic needs.